CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 109 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q1 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,089,273 | -30.9% | 141,515 | +0.7% | 0.00% | – |
| Q2 2023 | $4,468,085 | -33.5% | 140,550 | -49.0% | 0.00% | -100.0% |
| Q1 2023 | $6,716,421 | -5.2% | 275,376 | +22.6% | 0.00% | 0.0% |
| Q4 2022 | $7,083,001 | +123.1% | 224,572 | +99.9% | 0.00% | – |
| Q3 2022 | $3,175,000 | +436.3% | 112,360 | +401.7% | 0.00% | – |
| Q2 2022 | $592,000 | -74.8% | 22,397 | -66.7% | 0.00% | – |
| Q1 2022 | $2,352,000 | -5.8% | 67,190 | -12.8% | 0.00% | – |
| Q4 2021 | $2,497,000 | +137.4% | 77,018 | +116.0% | 0.00% | – |
| Q3 2021 | $1,052,000 | +691.0% | 35,655 | +587.1% | 0.00% | – |
| Q2 2021 | $133,000 | -35.4% | 5,189 | -65.4% | 0.00% | – |
| Q1 2021 | $206,000 | +20500.0% | 15,006 | +31162.5% | 0.00% | – |
| Q4 2020 | $1,000 | – | 48 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,005,284,000 | 38.09% |
| Ally Bridge Group (NY) LLC | 1,767,440 | $29,304,000 | 5.02% |
| Affinity Asset Advisors, LLC | 270,000 | $4,477,000 | 2.37% |
| SPHERA FUNDS MANAGEMENT LTD. | 811,665 | $13,457,000 | 1.19% |
| Artal Group S.A. | 2,282,100 | $37,837,000 | 0.81% |
| Perceptive Advisors | 4,544,062 | $75,340,000 | 0.81% |
| RA Capital Management | 2,200,000 | $36,476,000 | 0.51% |
| Monashee Investment Management LLC | 200,000 | $3,316,000 | 0.44% |
| Boxer Capital, LLC | 714,500 | $11,846,000 | 0.38% |
| EcoR1 Capital, LLC | 400,000 | $6,632,000 | 0.36% |